Company Profile
Tango Therapeutics Stock Price, News & Catalysts
- Ticker:
- TNGX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.29 USD (-1.21%)
Close
Last updated: August 17, 2026
3.11B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, TNGX closed down 1.21% at $25.29. No new same-company headline was identified in the current news window.
Company overview
Synthetic Lethality Oncology Company
Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss.
Vopimetostat
Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in RAS-mutant tumors.
RAS(ON) Combination Strategy
The company is combining vopimetostat with RAS(ON) inhibitors in pancreatic and lung cancers carrying both MTAP deletion and RAS mutations.
TNG456
TNG456 is a next-generation PRMT5 inhibitor being evaluated in glioblastoma and other MTAP-deleted cancers, extending Tango's synthetic-lethality strategy into tumors where brain penetration is important.
Future catalysts
- Phase 1/2 data for vopimetostat in combination with RAS(ON) inhibitors at the ESMO Congress on October 23–27, 2026.
- Vopimetostat monotherapy data in lung cancer in the second half of 2026.
- Initial clinical data for TNG456 in glioblastoma and other cancers in the second half of 2026.
- Initiation of a Phase 1/2 study of vopimetostat plus ERAS-0015 in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tango Therapeutics (TNGX)?
Tango Therapeutics (TNGX) most recently closed at 25.29 USD, a -1.21% move versus the previous session.
What is the market cap of Tango Therapeutics (TNGX)?
Tango Therapeutics currently has a market capitalization of 3.11B USD on BioPharmSignal.
What does Tango Therapeutics do?
Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in...
On which exchange is TNGX stock listed?
Tango Therapeutics (TNGX) is associated with NASDAQ, United States, Biopharma.
What is ERAS-0015?
Initiation of a Phase 1/2 study of vopimetostat plus ERAS-0015 in the second half of 2026.
Which conditions is Tango Therapeutics targeting with ERAS-0015?
Tango Therapeutics is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Tango Therapeutics describe recent progress with ERAS-0015?
Initiation of a Phase 1/2 study of vopimetostat plus ERAS-0015 in the second half of 2026.
What is vopimetostat?
Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers.